Skip to main content

Navigation group

Main content


The Translational Research category is interested in research that connects or moves the study in one discipline to another. Particularly for biomedicine, translational research is the research that relates basic and clinical research to medical or industrial application. As such, it includes a wide range of biological, medical, chemical, pharmacological, engineering, and computational studies that aim at elucidating the mechanism of a biological or disease related pathological function/process, or applying such mechanistic understanding to the generation of new knowledge/strategies with clinical or industrial implication. We are interested in publishing original and high-quality research that meets the goal and definition of translational research as described above. This may include (not limited to) studies in the following example areas: (1) identification or characterization of a biological target or signaling pathway involved in a disease pathology or therapeutic invention; (2) discovery and development of novel therapeutic or diagnostic methods or agents with implications for clinical or industrial application; (3) study of the mechanism of action of currently used drugs or new experimental agents at the molecular, cellular or systems level; (4) clinical research for novel experimental therapeutics or new applications of existing drugs or that reveals mechanistic insight into a disease process or new targets or approaches for clinical intervention or prevention; (5) development of new tools or methods by chemical, engineering, nanotechnology or computational techniques that can be applied to study biology or human diseases; and (6) genetic, proteomic or systems biological study to reveal new markers, pathways or targets for clinical application. Reports of pure clinical methods, tools, procedures, or observations without molecular, cellular or systems investigation of mechanism or insight into new mechanism or target for clinical treatment or detection are not acceptable. Studies of alternative medicine without mechanistic investigations as described above are also not accepted. For chemical, computational or engineering studies of molecular systems, some biological or clinical results must be presented, or in the absence of such data, such molecular systems should have clear potential for biological or medical application.

Associate Editor

Monica Jablonski, University of Tennessee Health Science Center, Hamilton Eye Institute, USA

Review Editors

Jing An, MD, PhD, University of California San Diego, USA

Roy Baynes, PhD, Merck Inc., USA

Yukai He, MD, PhD, Augusta University, USA

Hyacinth I. Hyacinth, MD, PhD, MPH, University of Cincinnati, USA

Chulso Moon, MD, PhD, HJM Research Foundation, USA

Esther A. Obeng, MD, PhD, St. Jude Children’s Research Hospital, USA

Jeffrey Schlom, PhD, National Cancer Institute, USA

Vivien Sheehan, MD/PhD, Emory University School of Medicine, USA

Advisory board and editorial team

SEBM’s Publications Committee and EBM’s Editorial Board provides strategic and professional advice to the Editor-in-Chief, Dr Steven Goodman. The journal recognises the following Editorial Board members for their continuous guidance and support of the journal: 


Steven R. Goodman, PhD, University of Tennessee Health Science Center, Memphis, TN, USA

Assistant to the Editor-in-Chief

Benjamin Zimmer, Society for Experimental Biology and Medicine, Washington D.C., USA

Africa Editor

Gordon Awandare, PhD, University of Ghana, Africa

Asia Editor

Shaw-Jeng Tsai, PhD, National Cheng-Kung University Medical College, Taiwan

Latin America Editor

Nicola Conran, PhD, University of Campinas, Brazil

Europe Editor

Farzin Farzaneh, PhD, King's College London, UK

Australia/Oceana Editor

Dr. Sulev Koks, Murdoch University, Perth, Australia

The full editor list for EBM can be found here.

Journal information

  • Short name

    Exp. biol. med.

  • Abbreviation


  • Electronic ISSN


  • Impact

    3.2 Impact Factor

    5.3 CiteScore

Journal categories

Open access statement

Open access logo

EBM provides online free gold open access to the journal and all of its research publications.

Open Access funder and institutional mandates: EBM is fully compliant with open access mandates, by publishing its articles under the Creative Commons Attribution license  (CC-BY). Funder mandates such as those by the Wellcome Trust (UK), National Institutes of Health (USA) and the Australian Research Council (Australia) are fully compatible with publishing in EBM. Authors retain copyright of their work and can deposit their publication in any repository. The work can be freely shared and adapted provided that appropriate credit is given and any changes specified.


Each EBM article strives for the highest quality, thanks to genuinely collaborative interactions between authors, editors and reviewers. EBM encourages authors to consult the instructions for authors guidelines prior to submission.


Frontiers Editorial Office

Avenue du Tribunal Fédéral 34

CH – 1005 Lausanne


Tel +41(0)21 510 17 40

Fax +41 (0)21 510 17 01

For queries regarding thematic issues, fee support, and any other questions, please contact

For all queries regarding manuscripts in review or potential conflicts of interest, please contact

EBM Editorial Offices

For any additional questions or queries, please contact

IT HelpDesk

Tel +41(0)21 510 17 10

Fax +41 (0)21 510 17 01

For technical issues, please visit our HelpDesk, or contact our IT HelpDesk team at